GlassScriptPhysician profile
Nancy R Glick
NPI 1083607881
$185,768.10
in general payments reported to CMS, 2019-2025
9 companies · $29K in 2025
The $29K reported for 2025 was more than what 97% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57K · 2020: $28K · 2021: $19K · 2022: $12K · 2023: $7,409 · 2024: $33K · 2025: $29K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $43K · Consulting Fee: $21K · Travel and Lodging: $2,645 · Food and Beverage: $2,514.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,452.50 |
| Consulting Fee | $21,371.41 |
| Travel and Lodging | $2,645.11 |
| Food and Beverage | $2,513.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $163,098.39 | 2019-2025 | Biktarvy, Descovy, Yeztugo |
| Viiv Healthcare Company | $22,230.71 | 2019-2025 | Cabenuva, Apretude, Dovato |
| Napo Pharmaceuticals INC | $174.74 | 2019 | |
| Emd Serono, INC. | $87.32 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $59.06 | 2019 | |
| Janssen Biotech, INC. | $47.65 | 2019-2020 | |
| Vyera Pharmaceuticals, LLC | $30.60 | 2019 | |
| Abbvie INC. | $21.44 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Glick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.